37 results about "Neuritis" patented technology

The present application relates to novel substituted heterocyclic carboxamides, to processes for their preparation, to their use alone or in combinations for the treatment and / or prevention of diseases and to their use for producing medicaments for the treatment and / or prevention of diseases, in particular for the treatment and / or prevention of breathing difficulties including sleep-induced breathing difficulties such as central and obstructive sleep apnoea, snoring (primary and obstructive snoring), dysphagia, peripheral and cardiac vascular disorders including diabetic microangiopathies and disorders of the peripheral and central nervous system including neurodegenerative and neuroinflammatory disorders.

The invention belongs to the technical field of medicines, and particularly relates to a phenanthroindolizidine alkaloid compound and application thereof. The invention discloses two kinds of phenanthroindolizidine alkaloid compounds, namely (-)-(R)-13a alpha-secoxanthin and (-)-(R)-13a alpha-6-O-desmylanthin, which are derived from a traditional Chinese medicine cynanchum atratum, and discloses the obvious anti-neuritis activity of the phenanthroindolizidine alkaloid compounds for inhibiting the generation of nitric oxide. Animal experiments prove that by intraperitoneal injection of the (-)-(R)-13a alpha-secoxanthin and the (-)-13a alpha-6-O-desmylanthin, the autonomous movement ability of a depression mouse is remarkably improved, the exploration behavior of the mouse is recovered, the anxiety symptom of the mouse is relieved, and the despair behavior of the mouse is relieved. The invention provides a new lead compound for research and development of new antidepressant drugs.

The invention provides a cassane diterpenoid compound and an application of the cassane diterpenoid compound in preparation of an anti-neuroinflammation medicine. Six novel cassane diterpenoid compounds are separated from mysorethorn, and a preparation method of the six compounds is provided. According to the present invention, the inhibition effect of lipopolysaccharide (LPS)-induced BV-2 microglial cells on NO production is determined, and the six compounds have anti-neuroinflammatory activity, and particularly, the compounds 4 and 5 have good anti-inflammatory effect compared with other compounds, and have the potential of anti-neuroinflammatory drug preparation.

The invention provides saCNTF-DSF-LNP composite nanoparticles as well as a preparation method and application of the saCNTF-DSF-LNP composite nanoparticles, and particularly relates to application of the saCNTF-DSF-LNP to preparation of medicines for treating diseases related to optic nerve injury. The method comprises the following steps: S1, preparing self-amplification CNTF RNA, and naming the self-amplification CNTF RNA as saCNTF; s2, preparing lipid nano particles entrapped with the disulfiram DSF; s3, quickly adding the ethanol phase containing the disulfiram DSF-lipid mixture into the aqueous phase containing the saCNTF, and mixing, so that the nanoparticles are formed by self-assembly; s4, purifying the nano particles by using an ultrafiltration centrifugal device to obtain saCNTF-DSF-LNP; the invention provides a preparation method and application of saCNTF-DSF-LNP, the saCNTF-DSF-LNP can inhibit neuroinflammation driven by acute pyroptosis, and continuous neurotrophic support is provided for RGC survival and long-term axon regeneration; according to saCNTF-DSF-LNP, continuous expression of CNTF is achieved through saRNA, efficient targeted delivery is achieved by means of LNP so as to reduce off-target toxicity of DSF, and a new treatment strategy is provided for neuritis and degenerative diseases.

The present disclosure provides single- or double-stranded interfering RNA molecules (e.g., siRNA) that target a SiglecS (CD33) gene. The interfering RNA molecules may contain specific patterns of nucleoside modifications and internucleoside linkage modifications, as pharmaceutical compositions including the same. The siRNA molecules may be branched siRNA molecules, such as di-branched, tri-branched, or tetra-branched siRNA molecules. The disclosed siRNA molecules may further feature a 5′ phosphorus stabilizing moiety and / or a hydrophobic moiety. Additionally, the disclosure provides methods for delivering the siRNA molecule of the disclosure to the central nervous system of a subject, such as a subject identified as having a neuroinflammatory disease (e.g., Alzheimer's disease).

The application discloses a sesquiterpene dimer and a preparation method and application thereof, and belongs to the technical field of natural compound extraction. According to the preparation method, dried sesquiterpene dimers are extracted by refluxing with 95% ethanol, and then petroleum ether and ethyl acetate are used for extraction to obtain an extract, which can be obtained by column chromatography and semi-preparative high performance liquid chromatography, so that the method is simple, time and labor are saved, and the yield is higher. The obtained sesquiterpene dimers have high anti-neuritis activity, and have important application prospects for developing new drugs for treating senile dementia.

The present invention relates to a DHP-I inhibitor for use in a method for the prophylactic and / or therapeutic treatment of a neuroinflammatory disease. In some embodiments, it relates to a DHP-I inhibitor for use in a method for the prophylactic treatment of neurodegeneration. The present invention also relates to a DHP-I inhibitor for use as neuroprotectant. It further pertains to related methods for the prophylactic and / or therapeutic treatment of a neuroinflammatory disease and the use of a DHP-I inhibitor in the manufacturing of a medicament for use in these methods. The present invention also provides pharmaceutical compositions and delivery systems for use in the methods of the invention, as well as to a pharmaceutical composition or drug delivery systems suitable for administration by a route bypassing the blood brain barrier (BBB) and / or the blood retinal barrier (BRB), preferably selected intrathecal, intracranial, intranasal and / or ocular administration; or suitable for trespassing the BBB and / or the BRB.

The present disclosure describes, compositions and methods comprising a recombinant, chimeric poliovirus construct for the neuroinflammatory stimulation of microglia against neurodegenerative diseases. The compositions may include a chimeric poliovirus and a therapeutic agent capable of binding to protein aggregates associated with the neurodegenerative disease. Methods of treating neurodegenerative diseases and methods of activating microglia are also provided.

The invention provides a pharmaceutical composition for treating herpes zoster as well as a preparation method and application thereof, and belongs to the technical field of medicines. Comprising the following components in parts by weight: 8-15 parts of sticky rice, 8-15 parts of mung beans, 1-3 parts of snake slough, 8-15 parts of flying centipedes, 1-3 parts of realgar and 1-5 parts of borneol. By adding the basic components including the sticky rice, the mung bean, the snake slough, the centipede, the realgar and the borneol, the traditional Chinese medicine composition can achieve the synergistic effects of resisting viruses, relieving pain, diminishing inflammation and the like, effectively relieves the symptoms of rash, pain and the like of herpes zoster, plays a role in neuroinflammation caused by viruses, is relatively mild in medicine property, and is free of toxic and side effects. The medicine is suitable for being used by herpes zoster patients with sensitive skin.

The present invention provides novel hydroquinone derivatives of formula (I), processes of preparation, as well as pharmaceutical compositions and methods of treating and / or preventing e.g. autoimmune, immunological, rheumatology, vascular disorders, ophthalmologic disorders, fibrotic disorders, metabolic and gastrointestinal disorders, neuroinflammatory and neurodegenerative diseases, neoplasms and cancer associated disorders, hormone related diseases and immunological disorders resulting from viral and bacterial infectious diseases and complications thereof. wherein R 1 is COOR 4, (CH 2 ) n COOR 4, SO 3 H, (CH 2 ) n SO 3 H or CONH-R 10; one of R 2 and R 3 is H and the other is R 5.

The present disclosure provides methods for treating an inflammatory disease or disorder, wherein the inflammatory disease or disorder is a neurodegenerative and / or neuroinflammatory disease or disorder, comprising administration of a GLP-1 receptor agonist (e.g., semaglutide, exendin-4), and an IL-2 protein (e.g., aldesleukin) to a subject. Also presented herein are compositions for use with the methods disclosed herein and kits for administering a GLP-1 receptor agonist (e.g., semaglutide, ex endin-4), and an IL-2 protein (e.g., aldesleukin).

The invention belongs to the technical field of medicines, and particularly discloses a novel 5-6-7-5 ring system beta acid compound, a preparation method thereof and application of the novel 5-6-7-5 ring system beta acid compound in neuroinflammation resistance. The novel 5-6-7-5 ring system beta acid compound provided by the invention is obtained by separation in nature for the first time, and has a good anti-neuroinflammation effect; the compound can be used for developing drugs for treating neuroinflammation related diseases, including but not limited to depression, Alzheimer's disease, Parkinson's disease, Huntington's disease, optic neuromyelitis, peripheral neuritis and the like.

The present invention relates to a pharmaceutical composition for the prevention or treatment of degenerative brain diseases, comprising abemaciclib as an active ingredient and, in particular, to: a pharmaceutical composition for the prevention or treatment of degenerative brain diseases, comprising abemaciclib or a salt thereof as an active ingredient; and a health functional food for the prevention or amelioration of degenerative brain diseases. Abemaciclib according to the present invention has excellent activity of inhibiting an inflammatory cytokine, i.e., COX-2, IL-1β, IL-6, or iNOS in brain neurons, has excellent activity of inhibiting TLR4 signaling related to inflammatory responses and inhibiting the level of p-STAT3, can inhibit the activity of microglia or astrocytes by LPS, also has the activities of inhibiting amyloid plaques, increasing the number of dendrites, and inhibiting the phosphorylation of tau protein, and can improve the long-term memory of mice with induced degenerative brain diseases. Therefore, abemaciclib of the present invention is effective in use as an active ingredient of medicines and health functional foods for preventing, ameliorating, or treating degenerative brain diseases or neuroinflammatory diseases.

This invention relates to the field of plant-derived extracellular vesicles, and discloses a method for preparing and applying Hypericum perforatum-derived exosome-like nanovesicles (HPDENs). This invention prepares HPDENs with natural vesicle structures through a specific process, utilizing the natural characteristics of plant-derived vesicles to encapsulate Hypericum perforatum (…). HP The active ingredient, combined with nasal drops, achieves targeted delivery to the brain. It exerts its antidepressant effect by regulating microglia polarization imbalance and reshaping the "neuroimmune-synaptic" axis. This solves the core problems of traditional antidepressants, such as slow onset of action, poor treatment response, and large side effects. It can also improve the core pathological features of depression (neuritis, synaptic plasticity damage) and improve depressive-like behaviors, providing a brand-new option for the clinical treatment of depression.

This invention discloses an acetamine-type sesquiterpene compound, its preparation method, and its applications, belonging to the field of natural compound extraction technology. The preparation method involves extracting dried *Elsholtzia ciliata* by reflux with 95% ethanol, followed by petroleum ether extraction to obtain an extract. The extract can be obtained by column chromatography and semi-preparative high-performance liquid chromatography. The method is simple, time-saving, labor-saving, and yields higher results. Furthermore, the obtained acetamine-type sesquiterpene compound exhibits high anti-neuritis activity, showing significant application potential for developing new drugs to treat neuritis-related diseases.

The invention provides an enteric-coated tablet for treating neuritis and a preparation method of the enteric-coated tablet. The enteric-coated tablet is prepared from the following components in percentage by weight: 0.01%-1% of mecobalamin, 60%-80% of butanedisulfonic acid adenosyl methionine, 10%-30% of a diluent, 4%-9% of an adhesive, 1%-5% of a disintegrating agent, 0.1%-1% of a lubricant and 8%-16% of an enteric-coated material. The enteric-coated tablet disclosed by the invention is simple in production process, universal in production equipment and low in cost, mainly overcomes the defect of large in-vivo absorption difference, and has a remarkable curative effect on treating neuritis.

The present disclosure relates to the field of oligonucleotides. More particularly, the present disclosure relates to antisense oligonucleotides for the specific binding and inhibition of translation of Chitinase (CHIT1) encoding mRNA. Additionally, this disclosure relates to methods of using such oligonucleotides in preventing or treating diseases, disorders or conditions associated with CHIT1, such as neurodegenerative or neuroinflammatory diseases, disorders or conditions like ALS.

Provided is to a compound or a pharmaceutically acceptable salt thereof for use in a composition for rejuvenating aged microglia, and a pharmaceutical composition for preventing or treating brain diseases containing the same. Also disclosed is the use of a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof to restore the phagocytic function of microglia that has been impaired by dexamethasone, thereby providing a rejuvenation composition for aged microglia that can be usefully applied as a pharmaceutical composition for preventing or treating brain diseases including neurodegenerative diseases, neuroinflammatory diseases, depression, and neuropsychiatric disorders.

Described herein are methods and compositions, for example a fixed dose oral composition, for treating a TYK2-mediated neuroinflammatory disease or disorder, and / or a TYK2-mediated neurodegenerative disease or disorder. In some embodiments, the TYK2- mediated disorder neuroinflammatory disease is, for example, multiple sclerosis.

This invention belongs to the field of biomedical technology and specifically relates to the use of divalent metal lactates in the manufacture of products for the prevention, improvement, repair, and treatment of nerve damage. Preferably, the divalent metal lactate includes one or more of the following: calcium lactate, magnesium lactate, zinc lactate, and ferrous lactate. This invention provides a novel treatment method for repairing damage to the central and peripheral nervous systems and has broad potential applications in the treatment and repair of central nervous system damage caused by trauma or other causes, or peripheral neuritis or peripheral nerve sensory abnormalities caused by viruses, diabetes, chemotherapy drugs, etc.

The invention discloses a Tibetan medicine anti-inflammation inunction preparation and a preparation method thereof, and belongs to the technical field of Tibetan medicines, and the Tibetan medicine anti-inflammation inunction preparation comprises rhubarb, alkali, oxytropis verticillata, herba achyranthis bidentatae, stellera chamaejasme, euphorbia macrocarpa, goethite, folium ilicis scandens, rock brain, volundaisy, gypsum rubrum, rhubarb, thalictrum aquilegifolium, codonopsis alpina, Perot, semen cassiae, abelmoschus esculentus seeds and lagotis diffusa. The medicament has the effects of promoting blood circulation to remove blood stasis, dispelling wind, eliminating dampness, relaxing tendons, dredging collaterals, diminishing inflammation and relieving pain. The traditional Chinese medicine composition can be used for treating joint swelling and pain, limb stiffness, limited activity, hand and foot spasm, neuralgia and other symptoms caused by vasculitis, varicosity, peripheral neuritis, rheumatism, rheumatoid arthritis, gout, fracture and the like, and has effective swelling and pain relieving effects.

Provided herein are compositions and methods for treating neuroinflammatory diseases and conditions, the neuroinflammatory diseases and conditions include Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), traumatic brain injury (TBI), complex regional pain syndrome (CRPS), optic neuritis (ON), optic neuromyelitis (NMO), chronic traumatic encephalopathy (CTE), ischemic stroke (IS), vascular dementia (VAD), anti-oligodendroglia glycoprotein antibody disease (MOGAD), and the like. Transverse myelitis (TM), autoimmune encephalitis (AE), acute disseminated encephalomyelitis (ADEM), chronic meningitis (CM), central nervous system (CNS) vasculitis, hashimoto encephalitis (HE), neurosarcoidosis (NS), multi-system atrophy (MSA), migraine, chemotherapy-induced pain or dementia-related pain.

This invention relates to methods and compositions for detecting, diagnosing, preventing, treating or ameliorating the symptoms of a demyelinating condition selected from: enterotoxemia (ET), multiple sclerosis (MS), clinically definite MS (CDMS), clinically isolated syndrome (CIS), neuromyelitis optica spectrum disorder (NMOSD), optic neuritis (ON), neuromyelitis optica (NMO), myelitis, myelitis, transverse myelitis (TM), a disease or condition characterised by the increase or presence of antibodies against aquaporin-4 (AQP-4) and / or astrocyte damage, and acute disseminated encephalomyelitis (ADEM) in a human or animal subject in need. The methods comprise administering to the subject a composition comprising an effective amount of an agent that directly or indirectly interferes with epsilon toxin (ETX) produced by Clostridium perfringens type B or type D bacterial strain, an ETX-binding receptor, or an interaction of ETX with its binding receptor so as to inhibit or suppress ETX modulated receptor signalling activities. The invention also provides novel polypeptides useful as a vaccine against diseases caused by or associated with the epsilon toxin of Clostridium perfringens.

The application provides a Dendrobium candidum exosome composition loaded with miR-146a and miR-124 and a preparation method and application thereof. The Dendrobium candidum exosome has an antioxidant function, miR-146a and miR-124 have a synergistic anti-inflammatory function, the Dendrobium candidum exosome provides a delivery carrier for miR-146a and miR-124 and improves the stability and anti-inflammatory function of miR-146a and miR-124, and finally a pharmaceutical composition EXE-miR-146a-124 for treating neuroinflammation and diseases related thereto is developed. The application not only provides a safe and efficient miRNA delivery system, but also endows the system with neuroprotective and anti-inflammatory effects, and provides a brand-new, natural source intervention scheme for the treatment of nervous system inflammatory diseases.

The application discloses a steroid pyrazole-thiazolone derivative containing thiophene and pyridine, a preparation method and application thereof. The steroid pyrazole-thiazolone derivative containing thiophene and pyridine provided by the application can significantly inhibit the production of NO (nitric oxide) of BV-2 microglial cells induced by LPS (lipopolysaccharide), wherein the anti-inflammatory activity of compound 2 is the most significant, the IC50 value of the compound 2 is 2.05 micromoles / L, which is superior to the positive control progesterone, and the compound 2 can inhibit the expression of downstream inflammatory proteins iNOS and COX-2 by inhibiting the NF-kappa B signal pathway, thereby exerting the anti-neuroinflammatory activity, and the compound 2 can be used for preparing a medicine for treating and / or preventing neurodegenerative diseases; the compound 2 is stable in structure, convenient to store, and can be developed as a lead derivative for preventing and treating neurodegenerative diseases (such as Alzheimer's disease), neuroinflammatory diseases and other related diseases.

The application belongs to the technical field of medicines, and specifically discloses a novel 5-6-7-5 ring system beta acid compound, a preparation method thereof and application of the compound in resisting neural inflammation. The novel 5-6-7-5 ring system beta acid compound is first separated from nature, has good anti-neural inflammation effect, and can be used for developing medicines for treating neural inflammation related diseases, including but not limited to depression, Alzheimer's disease, Parkinson's syndrome, Huntington's disease, opticospinal neuritis and peripheral neuritis.

This application relates to the pharmaceutical field, and specifically to a multi-TRP ion channel modulator, its preparation method, and its application. The multi-TRP ion channel modulator developed in this application can inhibit TRPV1, activate TRPM8, and activate TRPA1, and can be used to treat functional gastrointestinal disorders, intestinal mucosal damage, intestinal inflammation, immune dysregulation, gut microbiota imbalance, gastrointestinal tumors, pain, or peripheral neuritis.

The invention discloses a sesquiterpene dimer as well as a preparation method and application thereof, and belongs to the technical field of natural compound extraction. According to the preparation method, the dried sesquiterpene dimer is subjected to reflux extraction with 95% ethanol and then extracted with petroleum ether and ethyl acetate to obtain the extract, the extract can be obtained through column chromatography and semi-preparative high performance liquid chromatography, the method is simple, time and labor are saved, and the yield is higher. And the obtained sesquiterpene dimer has high anti-neuritis activity, and has an important application prospect for developing a new medicine for treating senile dementia.